Keyphrases
Early Alzheimer's Disease
100%
Phase II Trial
100%
Gantenerumab
100%
Placebo
50%
Positron Emission Tomography
30%
CDR-SB
30%
Confidence Interval
20%
Alzheimer's Disease
20%
Amyloid Plaques
20%
Change from Baseline
20%
Edema
20%
Amyloid Imaging
20%
Non-associated
10%
Cerebrospinal Fluid
10%
Placebo Groups
10%
Mild Cognitive Impairment
10%
Fluid Level
10%
Monoclonal Antibody
10%
Cognitive Impairment
10%
High Affinity
10%
Amyloid beta
10%
High-score
10%
Cognitive Decline
10%
Functional Decline
10%
Anti-A
10%
Clinical Dementia Rating
10%
Plaque Burden
10%
Trial Participants
10%
Fully Human
10%
Amyloid Status
10%
Clinical Decline
10%
Phosphorylated tau181
10%
Cerebrospinal Fluid Examination
10%
Centiloids
10%
Mild Dementia
10%
IgG1 Monoclonal Antibody
10%
Medicine and Dentistry
Alzheimer's Disease
100%
Gantenerumab
100%
Placebo
60%
Amyloid Protein
40%
Positron Emission Tomography
30%
Tau
20%
Cerebrospinal Fluid
20%
Amyloid Plaque
20%
Edema
20%
Monoclonal Antibody
20%
Mild Cognitive Impairment
10%
Cognitive Defect
10%
Clinical Dementia Rating
10%
Amyloid Beta
10%
Treatment of Alzheimer's Disease
10%
Immunoglobulin G1
10%
Blood Group A Antibody
10%
Rating Scale
10%
Neuroscience
Alzheimer's Disease
100%
Gantenerumab
100%
Placebo
60%
Amyloid Protein
60%
Positron Emission Tomography
30%
Monoclonal Antibody
20%
Cognitive Disorders
10%
Mild Cognitive Impairment
10%
Beta Amyloid
10%
Treatment of Alzheimer's Disease
10%
Blood Group A Antibody
10%
Clinical Dementia Rating
10%
Immunoglobulin G1
10%
Pharmacology, Toxicology and Pharmaceutical Science
Alzheimer's Disease
100%
Gantenerumab
100%
Placebo
60%
Amyloid Protein
50%
Monoclonal Antibody
20%
Edema
20%
Amyloid Plaque
20%
Cognitive Defect
10%
Blood Group A Antibody
10%
Mild Cognitive Impairment
10%
Immunoglobulin G1
10%
Immunology and Microbiology
Gantenerumab
100%
Positron Emission Tomography
30%
Monoclonal Antibody
20%
Cerebrospinal Fluid
10%
Blood Group A Antibody
10%
Immunoglobulin G1
10%
Cerebrospinal Fluid Level
10%